●Responsible for reviewing and providing scientific input to clinical protocols, informed consents, investigator brochures and site initiation visit (SIV) slides● Contribute to clinical data review plans, electronic case report form guidelines and subject enrollment forms● Aiding in reviewing patient profiles, clinical data in the EDC and ensuring compliance to the clinical protocol● Key contributor to the translational sciences program, in executing against the translational plan to support early decision-making as well in support against the CDx strategy. ● Working with program team leads to support the implementation and coordination of novel prognostic, pharmacodynamic biomarkers to enable science driven decisions ● Collaborating with several cross functional teams in business development, regulatory, market research and preclinical● Supporting external research collaborations enabling biomarker assay feasibility assessment and validation● Leading the design, analysis, review and interpretation of clinical biomarker data and presenting to key internal and external stakeholders● Supervising and having oversight of CROs, vendors and external collaborators

Managing immuno-oncology Phase I/II clinical trials.● Involved in the overall clinical trial execution including study initiation visits (SIVs), patient visits, local and central laboratory PK/PD collections, accurate data entry, per-protocol collection of radiographic disease assessments and data review● Acting as the primary point of contact between sponsors, physicians, and patients, supporting continuous communication and trial progress.● Working collaboratively with study monitors, sponsors, and principal investigators to ensure compliance with the approved standard operating procedures (SOPs), protocol/amendments, GCP, and the applicable regulatory requirements.● Performing data management activities through the initiation/updating of eCRF and query resolution in EDMS/CTMS.● Present at data safety monitoring meetings on the scientific rationale and inclusion criteria of open clinical trials to help increase patient recruitment.

Managing projects essential for characterizing the mechanism of action of novel NMDAR modulators in various rodent models of neurological disease• Informing clinical trial outcome program lead for the compounds in our pipelineo Work with cross-functional team leads to establish timelines, communicate expectations, and report on project statuso Identify which dosing paradigms has the most robust and long-lasting effect in behavioral animal models to ensure the most effective clinical outcome.• Communicate and establish relationships with outside CRO/vendorso Work to secure budget necessary for the initiation and completion of the projecto Ensure timely completion of projects by setting up follow-up meetings and setting deadlineso Review final reports and give feedback on more information that needs to be added for clarifications• Managing large datasetso Used multiple software platforms to identify NYX-compound mechanism of action via drug- and disease-specific proteomic profileso Streamlined and compiled all proteomic and transcriptomic studies• Designed and executed studies to assess brain regions and signaling processes necessary for the analgesic effect of NYX-2925 in neuropathic paino Identified Src as potential regulator of the analgesic effect of NYX-2925 and marker for sensitivityo Primary authored a manuscript in submission to Neurobiology of Pain• Improved and implemented departmental SOPs for immunoblotting to ensure assay reliability and reproducibility• Key developer of proteomic protocols• Responsible for troubleshooting receptor trafficking assay using microscopy and high throughput approaches• Presented project progress at team meetings, scientific workshops and conferences• Mentoring and training junior members of the department

Stratifying and identifying novel compounds that result in greater inhibition of tumor growth than current standard of care in breast cancer• Applied a novel computational algorithm capable of considering the expression of the whole transcriptome for breast cancer tumor expression data from the cancer genome atlas (TCGA) to predict various drugs’ sensitivity in tumors.• Identified and validated biomarkers that predict sensitivity to novel agents using enrichment analysis• Evaluated correlation between capecitabine response in patient-derived ex vivo model and patient• Performed high-throughput drug screens to discover novel agents that can overcome chemotherapy induced peripheral neuropathy using patient-derived peripheral neurons• Presented research and study data at meetings and conferences.

Circumventing Breast cancer endocrine resistance where the HER pathway becomes up-regulated and drives resistance.My studies looked into combining endocrine therapy with a novel HER1/2 tyrosine kinase inhibitor to overcome endocrine resistance or to delay endocrine resistance onsetA side project evaluated and characterized the tumor initiating cell population upon endocrine resistance

8week summer program in which i worked with Dr Debananda Pati, to understand the mechanism of cohesion complex during cell division.